Procept BioRobotics [PRCT] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Procept BioRobotics
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Procept BioRobotics wins in 4 metrics, Abbott Laboratories wins in 15 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Procept BioRobotics | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -19.85 | 16.75 | Procept BioRobotics |
| Price-to-Book Ratio | 5.14 | 4.59 | Abbott Laboratories |
| Debt-to-Equity Ratio | 20.57 | 26.50 | Procept BioRobotics |
| PEG Ratio | 0.66 | 0.46 | Abbott Laboratories |
| EV/EBITDA | -20.51 | 20.85 | Procept BioRobotics |
| Profit Margin (TTM) | -30.60% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | -28.02% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | N/A | 19.73% | N/A |
| Return on Equity | -26.40% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | -12.93% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $-103.62M | $6.35B | Abbott Laboratories |
| Dividend Yield | 0.64% | 1.28% | Abbott Laboratories |
| 1-Year Return | -52.11% | 18.07% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 7.42 | 5.39 | Abbott Laboratories |
| Enterprise Value | $1.76B | $238.75B | Abbott Laboratories |
| EV/Revenue Ratio | 6.41 | 5.54 | Abbott Laboratories |
| Gross Profit Margin (TTM) | 65.35% | 56.44% | Procept BioRobotics |
| Revenue per Share (TTM) | $5 | $25 | Abbott Laboratories |
| Earnings per Share (Diluted) | $-1.50 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 1.03 | 0.70 | Abbott Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Procept BioRobotics vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Procept BioRobotics | 0.20% | -6.00% | -12.05% | -40.19% | -39.73% | -58.15% |
| Abbott Laboratories | -0.36% | -0.24% | 1.16% | -0.84% | 0.80% | 17.23% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Procept BioRobotics | -52.11% | -13.09% | -13.00% | -13.00% | -13.00% | -13.00% |
| Abbott Laboratories | 18.07% | 30.65% | 21.29% | 217.47% | 424.82% | 549.05% |
News Based Sentiment: Procept BioRobotics vs Abbott Laboratories
Procept BioRobotics
News based Sentiment: MIXED
September presented a mixed bag for Procept BioRobotics, with strong Q2 earnings and positive analyst ratings countered by stock volatility, insider selling, and downward price target revisions. The conflicting signals create a complex investment picture, making it a significant month for the company's trajectory.
Abbott Laboratories
News based Sentiment: POSITIVE
Abbott Laboratories reported strong Q2 2025 earnings and raised its full-year guidance, leading to positive analyst upgrades and increased institutional investment. While the ongoing NEC litigation presents a risk, the overall narrative is positive, suggesting continued growth and profitability for the company.
Performance & Financial Health Analysis: Procept BioRobotics vs Abbott Laboratories
| Metric | PRCT | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $1.99B | $231.60B |
| Market Cap Category | Small cap | Mega cap |
| 10 Day Avg. Volume | 902,800 | 6,299,450 |
| 90 Day Avg. Volume | 951,347 | 5,376,593 |
| Last Close | $34.80 | $132.99 |
| 52 Week Range | $34.01 - $103.81 | $110.86 - $141.23 |
| % from 52W High | -66.48% | -5.83% |
| All-Time High | $103.81 (Nov 11, 2024) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -66.48% | -6.74% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.48% | 0.07% |
| Quarterly Earnings Growth | 0.48% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | -0.31% | 0.32% |
| Operating Margin (TTM) | -0.28% | 0.20% |
| Return on Equity (TTM) | -0.26% | 0.31% |
| Debt to Equity (MRQ) | 20.57 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.94 | $29.05 |
| Cash per Share (MRQ) | $5.44 | $4.18 |
| Operating Cash Flow (TTM) | $-83,214,000 | $9.04B |
| Levered Free Cash Flow (TTM) | $-59,140,124 | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.64% | 1.28% |
| Last 12-Month Dividend | $0.38 | $1.69 |
Valuation & Enterprise Metrics Analysis: Procept BioRobotics vs Abbott Laboratories
| Metric | PRCT | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -19.85 | 16.75 |
| Forward P/E | -26.83 | 25.87 |
| PEG Ratio | 0.66 | 0.46 |
| Price to Sales (TTM) | 7.42 | 5.39 |
| Price to Book (MRQ) | 5.14 | 4.59 |
| Market Capitalization | ||
| Market Capitalization | $1.99B | $231.60B |
| Enterprise Value | $1.76B | $238.75B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.41 | 5.54 |
| Enterprise to EBITDA | -20.51 | 20.85 |
| Risk & Other Metrics | ||
| Beta | 1.03 | 0.70 |
| Book Value per Share (MRQ) | $6.94 | $29.05 |
Financial Statements Comparison: Procept BioRobotics vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PRCT | ABT |
|---|---|---|
| Revenue/Sales | $69.16M | $10.36B |
| Cost of Goods Sold | $25.00M | $4.47B |
| Gross Profit | $44.16M | $5.89B |
| Research & Development | $16.40M | $716.00M |
| Operating Income (EBIT) | $-27.44M | $1.69B |
| EBITDA | $-22.39M | $2.66B |
| Pre-Tax Income | $-24.74M | $1.78B |
| Income Tax | N/A | $453.00M |
| Net Income (Profit) | $-24.74M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PRCT | ABT |
|---|---|---|
| Cash & Equivalents | $316.21M | $6.53B |
| Total Current Assets | $465.79M | $23.15B |
| Total Current Liabilities | $52.06M | $13.00B |
| Long-Term Debt | $77.83M | $12.74B |
| Total Shareholders Equity | $389.16M | $49.06B |
| Retained Earnings | $-570.72M | $47.72B |
| Property, Plant & Equipment | $21.26M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PRCT | ABT |
|---|---|---|
| Operating Cash Flow | $-11.65M | $1.42B |
| Capital Expenditures | $-1.84M | $-484.00M |
| Free Cash Flow | $-18.82M | $933.00M |
| Debt Repayment | N/A | $-1.00B |
| Common Stock Repurchase | N/A | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | PRCT | ABT |
|---|---|---|
| Shares Short | 8.15M | 18.07M |
| Short Ratio | 8.52 | 3.68 |
| Short % of Float | 0.17% | 0.01% |
| Average Daily Volume (10 Day) | 902,800 | 6,299,450 |
| Average Daily Volume (90 Day) | 951,347 | 5,376,593 |
| Shares Outstanding | 54.72M | 1.73B |
| Float Shares | 53.56M | 1.73B |
| % Held by Insiders | 0.05% | 0.01% |
| % Held by Institutions | 0.98% | 0.81% |
Dividend Analysis & Yield Comparison: Procept BioRobotics vs Abbott Laboratories
| Metric | PRCT | ABT |
|---|---|---|
| Last 12-Month Dividend | $0.38 | $1.69 |
| Last 12-Month Dividend Yield | 0.64% | 1.28% |
| 3-Year Avg Annual Dividend | $0.53 | $1.92 |
| 3-Year Avg Dividend Yield | 0.12% | 0.49% |
| 3-Year Total Dividends | $1.59 | $5.77 |
| Ex-Dividend Date | Mar 31, 2025 | Jan 15, 2025 |